Advertisement

Topics

Cilag collaborates with argenx to develop and commercialise cancer immunotherapy cusatuzumab

05:35 EST 4 Dec 2018 | PharmaBiz

Cilag GmbH International, an affiliate of the Janssen Pharmaceutical Companies of Johnson & Johnson, has entered into a worldwide collaboration and license agreement with argenx BVBA and argenx SE, to develop and commercialize cusatuzumab (ARGX─110).

Original Article: Cilag collaborates with argenx to develop and commercialise cancer immunotherapy cusatuzumab

NEXT ARTICLE

More From BioPortfolio on "Cilag collaborates with argenx to develop and commercialise cancer immunotherapy cusatuzumab"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Mergers & Acquisitions
Commercial and market reports on mergers and acquisitions in the biotechnology, pharmaceutical, medical device and life-science industries. Mergers and acquisitions (abbreviated M&A;) is an aspect of corporate strategy, corporate finance and manageme...

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...